Feb. 2, 2023
Nelson Mullins attorneys are representing Longevity Biomedical, Inc. in a business combination with Denali Capital Acquisition Corp. targeted to close in the second quarter of 2023 that will create a Nasdaq-listed biopharmaceutical company focused on advancing new technologies to promote human health and longevity.
Longevity Biomedical is a biopharmaceutical company focused on advancing new technologies across therapeutics, health monitoring and digital health solutions to increase human health. They aim to become a leading provider of longevity-related products and services designed to increase health span for the rapidly growing global aging population.
The Nelson Mullins attorneys on the deal team were Andrew Tucker, Nina Gordon, Jeffrey Perry, Fady Ghaly, and Kyla Wonder. They were supported by Matt Zischke, Wells Hall, Tim Wagner, Chris Hanson, Chris Casavale, and Kathy Deutsch.
Read Longevity Biomedical's press release here.
Established in 1897, Nelson Mullins is an Am Law 100 firm of more than 1,000 attorneys, policy advisors and professionals with 31 offices in 15 states and Washington, D.C. For more information, go to www.nelsonmullins.com.
These materials have been prepared for informational purposes only and are not legal advice. This information is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Internet subscribers and online readers should not act upon this information without seeking professional counsel.